Across TCGA pan-cancer cohorts, CDKN2AIPNLP3 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated CDKN2AIPNLP3 data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CDKN2AIPNLP3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CDKN2AIPNLP3 expression acts as an unfavorable survival marker.
OV, READ, and ACC are the cancer types where CDKN2AIPNLP3 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.